Work

Imatinib-Resistant BCR-ABL Mutant Cellular Screening Paradigm To Characterize Promising Small-Molecule Inhibitors: T315I-BCR-ABL Targeted Drug Discovery.

Year: 2006

Type: article

Source: Blood

DOI: 10.1182/blood.v108.11.2181.2181

Authors: Mohammad Azam, William C. Shakespeare, Chester Metcalf, Yihan Wang, Raji Sunderamoorthi, Xiaotan Zhu, Wei-Sheng Huang, Dong Zou, Mathew Thomas, Jan Romero, Jeff Keats, Qihang Xu, David Dalgarno, Tim Clackson, Tomi K. Sawyer, George Q. Daley

Institutions: Boston Children's Hospital, ARIAD Pharmaceuticals (United States)

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2589015506

FWCI:

Cites:

Cited by:

Related to: 10